N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma
Open Access
- 21 December 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-10
Abstract
Because glycosylation is one of the most common post-translational modifications of proteins and because changes in glycosylation have been shown to have a significant correlation with the development of many cancer types, we investigated the serum N-glycome used to diagnose, stage and evaluate the pathological outcomes in IgD multiple myeloma. Serum samples were available for 20 patients with IgD multiple myeloma, 41 patients with light chain multiple myeloma and 42 healthy control subjects. Serum N-glycans were released and analysed using DNA sequencer-assisted fluorophore-assisted capillary electrophoresis. Characteristic changes were revealed in the serum N-glycome of IgD myeloma. In particular, three N-glycans (NG1(6)A2F, Peak3; NG1(3)A2F, Peak4; NA2FB, Peak7) showed increased clinical value. The best area under the ROC curve of NG1(6)A2F to diagnose IgD myeloma was 0.981, with a 95.0% sensitivity and 95.2% specificity, and that of NG1(3)A2F was 0.936, with a 95.0% sensitivity and 78.6% specificity. The best area under the ROC curve of NA2FB/NG1(3)A2F to differentially diagnose IgD myeloma versus light chain myeloma was 0.744, with a 95.3% sensitivity and 50.0% specificity. The level of NG1(3)A2F was correlated with the international staging system, while the higher abundance of NA2FB presented in IgD myeloma was predictive of a shorter progression-free survival. The advent of serum N-glycan signatures may play a role in the diagnosis, staging and prognosis of IgD myeloma and will serve as the foundation for a precision medicine approach to this rare subtype of multiple myeloma.Keywords
Funding Information
- the Natural Science Foundation of China (No. 81101639; 81271925; 81301877)
- the General Program of Shanghai Health and Family Planning Commission (No 201540089)
This publication has 45 references indexed in Scilit:
- Novel Glycan Biomarkers for the Detection of Lung CancerJournal of Proteome Research, 2011
- Efficacy and outcome of autologous transplantation in rare myelomasHaematologica, 2010
- Core fucosylation and 2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasiaGlycobiology, 2010
- APRIL and TACI interact with syndecan‐1 on the surface of multiple myeloma cells to form an essential survival loopEuropean Journal of Haematology, 2009
- The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorBlood, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyBlood, 2007
- Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myelomaOncogene, 2006
- Immunoglobulin D myeloma – Problems with diagnosing and staging (own experience and literature review)Leukemia & Lymphoma, 2005
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003